The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors
Official Title: A Phase 1 Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors
Study ID: NCT04900818
Brief Summary: This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 in subjects with advanced or metastatic solid tumors.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Stern Center for Cancer Clinical Trials and Research, Orange, California, United States
UCHealth Cancer Care - Anschutz Medical Campus, Aurora, Colorado, United States
Horizon Oncology Research, LLC., Lafayette, Indiana, United States
Mass General Hospital, Boston, Massachusetts, United States
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
NYU Langone, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Carolina BioOncology Institute, Huntersville, North Carolina, United States
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Mary Crowley Cancer Research, Dallas, Texas, United States
UW Carbone Cancer Center, Madison, Wisconsin, United States
Beijing Cancer Hospital, Beijing, Beijing, China
Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Hubei Cancer Hospital, Wuhan, Hubei, China
The First Hospital of China Medical University, Shenyang, Liaoning, China
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hongzhou, Zhejiang, China